Court rules that a patent for Lilly's ADHD drug Strattera is invalid

08/12/2010 | Reuters

The U.S. District Court for the District of New Jersey invalidated Eli Lilly and Co.'s method-of-use patent for Strattera, a treatment for ADHD. "Assuming a launch of a generic version of Strattera in the United States, the loss of revenue will undoubtedly add to the challenges we will face during upcoming patent expirations on other key products," CEO John Lechleiter said in a statement.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC